DexCom (NASDAQ:DXCM) is a medical device company headquartered in San Diego, California, specializing in continuous glucose monitoring (CGM) systems for people with diabetes. The company develops, manufactures, and distributes advanced sensor-based technology designed to provide real-time glucose readings, trend data, and alerts. DexCom’s CGM platforms integrate with mobile devices, wearable insulin pumps, and digital health applications to help users and healthcare professionals make informed decisions on diabetes management.
DexCom’s flagship products include the G6 and G7 CGM systems. These systems feature small, disposable sensors that measure interstitial glucose levels every few minutes and transmit data wirelessly to a receiver or smartphone app. The G6 system was introduced in 2018 and offers factory calibration and customizable alerts, while the G7, launched in late 2022, further reduces sensor size and warm-up time. Both systems are compatible with major insulin delivery devices and support integration with telehealth platforms.
Since its founding in 1999, DexCom has grown from a small startup into a global leader in glucose monitoring technology. The company achieved its first U.S. Food and Drug Administration (FDA) approval for a CGM sensor in 2006 and expanded its regulatory clearances to Europe, Canada and parts of the Asia Pacific region over the following decade. DexCom invests heavily in research and development to advance sensor accuracy, extend wear time and enhance connectivity with digital health ecosystems.
Under the leadership of President and Chief Executive Officer Kevin Sayer, who has helmed the company since 2011, DexCom continues to pursue strategic partnerships with device manufacturers, software developers and healthcare providers. The company serves a diverse customer base that includes people with type 1 and type 2 diabetes, endocrinology clinics and integrated healthcare systems, aiming to improve glycemic control and reduce the risk of diabetes-related complications worldwide.
